PLAGL2 promotes HCC progression by recruiting tumour‐associated macrophages via CCL2/CCR2 signalling
British Journal of Pharmacology · 2026-05 · 183 (9) · 2061-2079
DOI: 10.1111/bph.70295 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 17.12.2025. Verfasst von Yumeng Shen und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Receptors, CCR2, Liver Neoplasms, Chemokine CCL2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: The Outstanding Youth Program of the Lingang Laboratory, National Natural Science Foundation of China, Jiangsu Outstanding Youth Foundation.
Abstract (Originalsprache)
Background and Purpose Tumour‐associated macrophages (TAMs) constitute the predominant cell population within the tumour microenvironment and play a crucial role in promoting the progression of primary hepatocellular carcinoma (HCC). Our previous study has identified PLAGL2 as a driver of HCC progression; however, the comprehensive regulation of PLAGL2 on the immunosuppressive microenvironment of HCC has not been fully elucidated. The objective of this study is to elucidate the molecular mechanism by which PLAGL2 regulates TAMs. Experimental Approach Mouse orthotopic liver cancer, subcutaneous tumour, and in vitro co‐culture models demonstrated PLAGL2's regulation of TAM recruitment/polarisation. Single‐cell sequencing and Flow cytometry assessed immune cell subpopulation changes. Key Results Our study found that the expression of PLAGL2 was positively correlated with the recruitment of TAMs, M2 polarisation and poor prognosis. PLAGL2 promoted macrophage migration and M2 polarisation in vitro and in vivo. Single‐cell analysis revealed that overexpression of PLAGL2 in HCC cells mainly recruited CCR2 + macrophages. Deletion of macrophages attenuated the promotion of HCC growth by PLAGL2. Mechanistically, PLAGL2 directly participated in the transcriptional regulation of CCL2, thereby initiating its transcription and expression. Moreover, pharmacological inhibition of CCR2 significantly inhibited PLAGL2‐induced HCC progression, TAM recruitment and M2 polarisation. Conclusions and Implications PLAGL2 participates in the chemotaxis of TAMs and the regulation of M2 polarisation through the CCL2–CCR2 axis, thereby promoting an immunosuppressive microenvironment in HCC. Additionally, this study demonstrated that PLAGL2 serves as a novel transcription factor for CCL2, suggesting that PLAGL2 is a potential drug target for the treatment of HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
- Institute of Translational Medicine, China Pharmaceutical University, Nanjing, China.
- Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing, China.
- School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
- Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
- Lingang Laboratory, Shanghai, China.
ORCID-Profile: Weiwei Hu
Förderung
- The Outstanding Youth Program of the Lingang Laboratory
- National Natural Science Foundation of China
- Jiangsu Outstanding Youth Foundation
- 'Double First-Class' University Project
- Scientific Research Foundation for Talented Scholars
- the Project of the State Key Laboratory of Natural Medicines, China Pharmaceutical University
- Jiangsu Province Public Service Platform for Rapid Translation of Anti-Tumour New Drugs
Zitieren
APA
Shen, Y., Zhai, D., Zhao, W., Chen, Y., Ni, J., Li, J., Wu, Z., Xu, Y., Li, B., Zhuang, S., & Hu, W. (2026). PLAGL2 promotes HCC progression by recruiting tumour‐associated macrophages via CCL2/CCR2 signalling. British Journal of Pharmacology, 183(9), 2061-2079. https://doi.org/10.1111/bph.70295
Vancouver
Shen Y, Zhai D, Zhao W, Chen Y, Ni J, Li J, et al. PLAGL2 promotes HCC progression by recruiting tumour‐associated macrophages via CCL2/CCR2 signalling. British Journal of Pharmacology. 2026;183(9):2061-2079. doi:10.1111/bph.70295
BibTeX
@article{Shen2026,
author = {Shen, Yumeng and Zhai, Dongqing and Zhao, Weijun and Chen, Yuyuan and Ni, Jiaping and Li, Jingtong and Wu, Zijie and Xu, Yanchao and Li, Binghua and Zhuang, Shentian and Hu, Weiwei},
title = {PLAGL2 promotes HCC progression by recruiting tumour‐associated macrophages via CCL2/CCR2 signalling},
journal = {British Journal of Pharmacology},
year = {2026},
volume = {183},
number = {9},
pages = {2061--2079},
doi = {10.1111/bph.70295}
}
EUVIMED